These reviews should assess: Weight loss progress and tolerability Blood glucose control (particularly in diabetic patients) Cardiovascular risk factors Nutritional status and dietary adequacy Any new symptoms or adverse effects Mental health and eating behaviours Patients can optimise safety by: Following the prescribed dose escalation schedule to minimise side effects Maintaining adequate nutrition despite reduced appetite Discussing nutritional needs with a dietitian, particularly if dietary intake is significantly reduced Monitoring blood glucose levels if diabetic, as Wegovy may necessitate adjustment of other diabetes medications Staying well-hydrated, especially if experiencing gastrointestinal side effects Reporting any new or concerning symptoms promptly Healthcare professionals and patients should report suspected adverse reactions through the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk), contributing to ongoing safety surveillance
Mayo Clinic describes how semaglutide reduces appetite and supports weight management when paired with diet and activity
Anyone can follow the GOLO for Life Plan successfully
Growing concerns over compounded and unapproved products Compounded drugs may be appropriate only when a patients medical needs cannot be met by an FDA-approved medication, according to the agency
The Plateau Is Not the Drug Quitting Eventually the weight loss slows and stops
Without support, some people notice: Increased hunger Stronger cravings Gradual weight regain This doesnt mean semaglutide failed
